MindBio Therapeutics Corp. Stock Price

MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Australasia. The company engages in researching, developing, and testing microdosing of psychedelic substances as a potential treatment for the management of various mental health conditions, such as depression, anxiety, chronic pain, cognitive impairment, post-traumatic stress disorder, panic disorder, and opiate addictions. It also establishes and executes research protocols through formal clinical trials that are facilitated via digital therapeutic platforms; and invests in research for developing treatments for depression, anxiety, PTSD and chronic pain. In addition, the company develops MB22001, which is in Phase 2 clinical trial, for the treatment of major depressive disorder, as well as existential distress, anxiety, and depression associated with advanced stage cancer; and wearable devices to collect biometric data in mental health patients taking psychedelic medicines. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.